Housey Pharmaceutical Research Laboratories

Housey Pharma is a unique hybrid entity combining internal therapeutic development with a successful technology licensing business. Its core strategy involves leveraging proprietary, internally invented drug discovery platforms to advance its own pipeline while generating revenue through licensing agreements with major pharmaceutical companies like Novartis. The company's pipeline includes both prescription therapeutics and a marketed product, Axulin, and is supported by a leadership team and advisory board with deep industry and scientific expertise. Its dual model of platform licensing and product development positions it in both the technology and therapeutics sectors of biopharma.

Proprietary cell-based assay technologies for lead optimization and modulators of drug-resistant mutants (Theramuteins) for oncology; platforms are patented and commercially licensed.

Competes in the crowded oncology and diabetes therapeutic spaces against much larger, resource-rich pharmaceutical companies. Its technology platform business competes with other drug discovery tool and CRO companies, but its patented focus on drug-resistant mutants provides a niche differentiation.